Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial

• Published in: Epilepsia (Copenhagen) Vol. 63; no. 2; pp. 426 - 439
• Main Authors: Thiele, Elizabeth A., Bebin, E. Martina, Filloux, Francis, Kwan, Patrick, Loftus, Rachael, Sahebkar, Farhad, Sparagana, Steven, Wheless, James
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2022; John Wiley and Sons Inc
• Subjects: Adolescent; Adult; Anticonvulsants - adverse effects; antiseizure medication; Appetite loss; Cannabidiol; Cannabidiol - adverse effects; Cannabinoids; Caregivers; Child; Child, Preschool; Convulsions & seizures; Diarrhea; epilepsy; focal seizures; Humans; Infant; Middle Aged; Patients; Seizures; Seizures - drug therapy; Seizures - etiology; Treatment Outcome; treatment‐resistant epilepsy; Tuberous sclerosis; Tuberous Sclerosis - complications; tuberous sclerosis complex; Valproic acid; Young Adult; cannabidiol; epilepsy; focal seizures; antiseizure medication; treatment-resistant epilepsy; tuberous sclerosis complex

Objective To evaluate the long‐term safety and efficacy of add‐on cannabidiol (CBD) in patients with seizures associated with tuberous sclerosis complex (TSC) in the open‐label extension (OLE) of the randomized, placebo‐controlled phase 3 trial GWPCARE6 (NCT02544763). Results of an interim (February...